{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Percent of participants with Disease-Free survival (DFS) at 3 years. Assessed from date of treatment to date of death or date of disease progression, and to date of last follow-up for those still alive and progression free. Disease-free Survival percentages were calculated using Kaplan-Meier estimates.","groups":[{"description":"docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG000","title":"Oral Erlotinib Hydrochloride"}],"paramType":"NUMBER","populationDescription":"Participants enrolled in study","reportingStatus":"POSTED","timeFrame":"3 yrs after treatment","title":"Percent of Participants With Disease-Free Survival (DFS) at 3 Years","type":"PRIMARY","unitOfMeasure":"Percent"}